| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PATH.931 |
| P698 | PubMed publication ID | 11592104 |
| P50 | author | Stephen Fox | Q30506440 |
| Adrian Harris | Q37374768 | ||
| P2093 | author name string | Kakolyris S | |
| Taylor M | |||
| Gatter KC | |||
| Grøndahl-Hansen J | |||
| P2860 | cites work | What Is the Evidence That Tumors Are Angiogenesis Dependent? | Q29620029 |
| Thymidine phosphorylase is angiogenic and promotes tumor growth. | Q34672542 | ||
| The urokinase receptor: involvement in cell surface proteolysis and cancer invasion | Q35240620 | ||
| Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas | Q35977650 | ||
| Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours | Q35993235 | ||
| Urokinase and macrophages in tumour angiogenesis | Q36081712 | ||
| The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium | Q36134978 | ||
| Upregulation of urokinase receptor expression on migrating endothelial cells | Q36232769 | ||
| Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? | Q36237406 | ||
| Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. | Q36292147 | ||
| Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods | Q36292537 | ||
| Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation | Q36618743 | ||
| Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. | Q36641325 | ||
| Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer | Q36682140 | ||
| Plasminogen activator inhibitor-1 and prognosis in primary breast cancer | Q36735207 | ||
| In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis | Q37293011 | ||
| JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections | Q39651804 | ||
| Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition | Q39808694 | ||
| Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal | Q40848490 | ||
| The distribution of LH39 basement membrane epitope in the tumour stroma of oral squamous cell carcinomas. | Q41093873 | ||
| Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells | Q41144930 | ||
| Tumour angiogenesis and prognosis. | Q41411933 | ||
| The urokinase-type plasminogen activator system in cancer metastasis: A review | Q41522331 | ||
| Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer | Q41912805 | ||
| Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer | Q44212210 | ||
| A novel lamina lucida component of epithelial and endothelial basement membranes detected by LH39 monoclonal antibody | Q44705148 | ||
| Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. | Q47697374 | ||
| Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF | Q58212357 | ||
| Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study | Q58212436 | ||
| Tumor angiogenesis in node-negative breast carcinomas ? relationship with epidermal growth factor receptor, estrogen receptor, and survival | Q58212481 | ||
| Plasminogen activators (urokinase) mediate neovascularization: possible role in tumor angiogenesis | Q68979736 | ||
| Urokinase-type plasminogen activator antigen and early relapse in breast cancer | Q69375603 | ||
| Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer | Q70565913 | ||
| Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues | Q71089140 | ||
| Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer | Q72282479 | ||
| Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine | Q72852182 | ||
| Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients | Q73297547 | ||
| Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues | Q74295870 | ||
| Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression | Q77959324 | ||
| P433 | issue | 2 | |
| P921 | main subject | microvasculature remodeling | Q6840464 |
| plasminogen | Q107129060 | ||
| P304 | page(s) | 236-243 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Journal of Pathology | Q400296 |
| P1476 | title | Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer | |
| P478 | volume | 195 |
| Q37137516 | A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells |
| Q51525609 | Assessing Tumor Angiogenesis in Histological Samples. |
| Q64929513 | Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer. |
| Q36647843 | Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients |
| Q57581296 | Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer |
| Q37939968 | Liposomal nanomedicine for breast cancer therapy |
| Q34996841 | Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1 |
| Q40592761 | Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density |
| Q36067470 | Quantitative detection of common deletion of mitochondrial DNA in hepatocellular carcinoma and hepatocellular nodular hyperplasia |
| Q35810123 | Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature |
| Q35016807 | The macrophage growth factor CSF-1 in mammary gland development and tumor progression |
| Q34668320 | The prognostic molecular markers in hepatocellular carcinoma |
| Q82045223 | Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression |
| Q37392608 | Transforming growth factor-β promotes aggressiveness and invasion of clear cell renal cell carcinoma |
| Q29614307 | Tumour-educated macrophages promote tumour progression and metastasis |
| Q33762745 | Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy |
Search more.